Complementemia in pregnancies with antiphospholipid syndrome

Silvia Salvi, Antonio Lanzone, Sara De Carolis, Angela Botta, S. Tabacco, A. Giannini, C. Garufi, P. Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

4 Citazioni (Scopus)


Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
Lingua originaleEnglish
pagine (da-a)1503-1509
Numero di pagine7
Stato di pubblicazionePubblicato - 2019


  • Anticardiolipin antibodies
  • antiphospholipid syndrome
  • complement
  • complement activation
  • lupus anticoagulant
  • pregnancy


Entra nei temi di ricerca di 'Complementemia in pregnancies with antiphospholipid syndrome'. Insieme formano una fingerprint unica.

Cita questo